Gene editing therapy for bubble boy disease has a money back guarantee

ADA-SCID, commonly known as bubble boy disease, is a immune system disease caused by a mutation in the adenosine deaminase gene. It is commonly treated by bone marrow transplantion from a donor. Now, pharmaceutical company GlaxoSmithKline has developed an new gene editing therapy called Strimvelis, which uses retroviral gene editing to insert a healthy gene into a patient’s own cells, with a money back guarantee if it doesn’t work. Read more about the implications of this in a CNN article by Susan Scutti, featuring commentary by our PI, Dr. Hoggatt:

Learn More.